A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age60-80
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The purpose of this study is to look at how differences in cognitive (mental) function develop over time in breast cancer survivors compared to volunteers without a history of cancer (healthy volunteers). Both cancer survivors and healthy volunteers (who are the same age as the cancer survivors) will participate in this study so the researchers can compare the results of neurocognitive testing (which looks at memory, attention, and information processing) on each group of participants.

Eligibility criteria

Qualifiers

Per medical record and/or self-report, identifies as female

Per medical record and/or self-report, currently age 60-80

Per self-report, has access to a computer and internet connectivity

Score of <11 on Blessed Orientation-Memory-Concentration Test (BOMC)

Disqualifiers

As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.)

As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation

As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder.

As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids)

Trial design

Treatments tested in this trial

  • Assessments
  • Assessment (Survivors Only)
  • APOE and DNA Isolation

Treatment groups

420 Participants
are divided into 2 treatment groups